Atypical/malignant urothelial cells in routine urinary sediment: Worth knowing and reporting

Fogazzi, Giovanni B.; Pallotti, Francesco; Garigali, Giuseppe

doi:10.1016/j.cca.2014.10.021

Cited by 14 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in patient samples, we also identified cells with increased nuclear/cytoplasmic (N/C) ratio, irregular nuclear borders and irregular chromatin patterns. Cells were found either isolated or in clusters, exhibiting various shapes and sizes, including CMV-like atypical cells with an “eye-bird” appearance ( Figure 4A4 ); cells with enlarged nucleus or multinucleated ( Figures 4A5,6 ), clusters of atypical cells ( Figure 4A7 ), spindle-like cells ( Figure 4A8 ), and granular membrane atypical cells ( Figure 4A9 ), as previously reported ( 46 – 48 ). We further evaluated the shape deformation of captured urothelial exfoliated cells as they squeeze through the posts of the UriChip.…”

Section: Resultssupporting

confidence: 76%

Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies

et al. 2020

View full text Add to dashboard Cite

Bladder cancer is the most common malignancy of the urinary tract, having one of the highest recurrence rates and progression from non-muscle to muscle invasive bladder cancer that commonly leads to metastasis. Cystoscopy and urine cytology are the standard procedures for its detection but have limited clinical sensitivity and specificity. Herein, a microfluidic device, the UriChip, was developed for the enrichment of urothelial exfoliated cells from fresh and frozen urine, based on deformability and size, and the cancer-associated glycan Sialyl-Tn explored as a putative bladder cancer urinary biomarker. Spiking experiments with bladder cancer cell lines showed an isolation efficiency of 53%, while clinical sample analyses revealed retention of cells with various morphologies and sizes. in situ immunoassays demonstrated significantly higher number of Sialyl-Tn-positive cells in fresh and frozen voided urine from bladder cancer patients, compared to healthy individuals. Of note, urothelial exfoliated cells from cryopreserved urine sediments were also successfully isolated by the UriChip, and found to express significantly high levels of Sialyl-Tn. Remarkably, Sialyl-Tn expression is correlated with tumor stage and grade. Overall, our findings demonstrate the potential of UriChip and Sialyl-Tn to detect urothelial bladder cancer cells in follow-up and long-term retrospective studies.

show abstract

Section: Resultssupporting

confidence: 76%

Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Photographs of crystals mostly reflect antibiotics and radiologic contrast agents no longer in use. The increasing emphasis on urinary cytology to screen for malignancies will require laboratorians to become familiar with the appearance of malignant cells in the unstained specimens encountered in the clinical laboratory [13].…”

Section: Urine Proficiency Testing Issuesmentioning

confidence: 99%

External Quality Assessment Programs in the US with an emphasis on urinary sediment testing: the College of American Pathologists experience

Glassy¹,

Blomberg

2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

The College of American Pathologists (CAP) has maintained the highest standards for laboratory medicine through education, evaluation, and certification. One form of External Quality Assurance - proficiency testing (PT) - is the centerpiece of that mission. Over 500 medical and scientific experts oversee CAP PT programs which include more than 600 tests performed by 22,000 laboratories in over 100 countries. It is the most comprehensive laboratory peer-review comparison program in the world. The CAP offers four urine sediment PT products tailored to the needs of different laboratories. Each includes three or four digital images, shipped twice a year. The program is overseen by the Hematology and Clinical Microscopy Resource Committee. Images are graded if there is 80% or greater consensus of either referee or participant laboratories. Failing laboratories must analyze the reasons for the failure, report the results, and initiate corrective action. Over the years, there has been a progressive decline in the number of errors, demonstrating that education and regulatory oversight are major contributors to improved PT performance and, by extension, patient care. The PT urine sediment image databank is a unique resource, representing the consensus of many laboratories. Participant and referee responses identify which morphologic variants are unambiguous and which are more difficult to classify. The PT challenges include discussions of disease pathophysiology and key morphologic features. This teaching component is what helps to set the CAP's program apart. The discussions formed the basis for the Color Atlas of Urinary Sediment published by the CAP in 2010.

show abstract

“…Unfortunately, urinary cytology is performed in the pathology department and most laboratory medicine departments separate the routine urinalysis from urinary cytopathology. Some researchers have shown that atypical/malignant urothelial cells can be identified in routine urinalysis with the conventional urinary sediment examination or automated urinalysis [6,7]. Urothelial cells, either atypical or malignant, should be noted and are worth reporting in routine urinalysis specimens.…”

Section: Introductionmentioning

confidence: 99%

“…This provides important clues for a suspected diagnosis or the surveillance of urothelial carcinoma patients. Routine urinalysis can be used to identify atypical/malignant urothelial cells using automated digital or manual microscopy, but no studies have investigated the ability of the UF-5000 to detect atypical/ malignant urothelial cells [6,7]. Therefore, this study evaluated the performance of a new parameter, Atyp.C, in patients with a suspected diagnosis of urothelial carcinoma on urinary tract cytology (UTCy).…”

Section: Introductionmentioning

confidence: 99%

Investigation of Atyp.C using UF-5000 flow cytometer in patients with a suspected diagnosis of urothelial carcinoma: a single-center study

et al. 2020

View full text Add to dashboard Cite

Background This study evaluated the predictive power of Atyp.C (a parameter of UF-5000 flow cytometer) for patients with a suspected diagnosis of urothelial carcinoma. Methods We analyzed 163 urine specimens from 128 patients with suspected urothelial carcinoma using a fully automated fluorescence flow cytometry analyzer (UF-5000) and evaluated its performance on identifying atypical/malignant urothelial cells. From January 1, 2019 to April 4, 2019, all consecutive specimens for urinary cytopathology were enrolled. Results Of the specimens with urinary cytopathology, 67 specimens (41.1%) revealed abnormal findings in cytology analysis. Among them, 20 specimens (12.3%) were diagnosed as atypical urothelial cells, 26 specimens (16.0%) as suspicious for malignancy (S-malignancy), and 21 specimens (12.9%) as confirmed malignancy. The UF-5000 findings were positive in 59 specimens (36.2%); therefore, the agreement with cytopathology was 73.0%. Using follow-up histologic diagnosis of urothelial carcinoma with or without urinary tract cytology (UTCy) as a reference standard (suspicious and confirmed malignancy were the positive criteria for UTCy), the sensitivity was 59.0%, specificity was 82.1%, positive predictive value was 75.0%, negative predictive value was 68.8%, and the agreement was 71.1%. Conclusions It is worth knowing and reporting that the Atyp.C assay may be used as an accessory test for patients with suspected urothelial carcinoma, based on its ability to identify high-risk patients who might need closer follow-up or additional medical treatment.

show abstract

Atypical/malignant urothelial cells in routine urinary sediment: Worth knowing and reporting

Cited by 14 publications

References 16 publications

Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies

Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies

External Quality Assessment Programs in the US with an emphasis on urinary sediment testing: the College of American Pathologists experience

Investigation of Atyp.C using UF-5000 flow cytometer in patients with a suspected diagnosis of urothelial carcinoma: a single-center study

Contact Info

Product

Resources

About